This review examines mechanistic evidence linking metabolic dysfunction in type 2 diabetes (T2DM) to cerebrovascular impairment and cognitive decline, and places nitric oxide (•NO) at the center of those mechanisms. The authors synthesize data supporting a model in which chronic hyperglycaemia and insulin resistance reduce •NO bioavailability within the neurovascular unit (NVU), producing a redox imbalance that compromises vascular, metabolic, and neuronal interactions. The resulting vascular remodelling, disrupted neurovascular coupling (NVC), and impaired regional perfusion are presented as drivers of progressive cognitive impairment. Specific clinical trial outcomes or therapeutic protocols are not reported in the abstract.
In physiological conditions, •NO acts as a diffusible, pleiotropic messenger that integrates vascular and metabolic responses to neuronal activity. Neuronal activity triggers Ca2+-dependent activation of neuronal nitric oxide synthase (nNOS), producing •NO that diffuses to adjacent microvessels and promotes vasodilation via the soluble guanylyl cyclase (sGC)–cGMP–PKG pathway. Endothelial •NO, produced in response to shear stress and via PI3K–Akt–dependent activation of endothelial nitric oxide synthase (eNOS), contributes further to basal vascular tone and flow regulation.
Beyond vasodilation, •NO modulates cellular metabolism within the NVU: it influences astrocytic glycolysis and lactate shuttling to neurons, supporting mitochondrial ATP generation and helping to match energy supply to neuronal demand. This coordinated signalling underlies effective neurovascular coupling and preserves regional cerebral perfusion during increased neuronal activity.
The review identifies multiple, converging mechanisms by which T2DM lowers •NO bioavailability and shifts the redox balance toward oxidative stress. Key mechanisms outlined include:
Together, these processes produce a state of nitro-oxidative stress within the NVU and cerebrovascular network. The abstract notes these pathways as central routes by which chronic hyperglycaemia and insulin resistance converge to reduce •NO in T2DM.
Reduced •NO bioavailability and increased nitro-oxidative stress are described as compromising both the functional and structural integrity of the cerebrovascular network. Consequences highlighted in the review include:
These changes shift the local cerebrovascular environment toward oxidant-mediated damage and reduced responsiveness to physiological stimuli, undermining dynamic regulation of cerebral blood flow.
According to the integrated model in the review, impaired NVC and reduced regional perfusion produce a sustained mismatch between energy supply and neuronal demand. Metabolically vulnerable brain regions, such as the hippocampus, are particularly susceptible to such chronic bioenergetic deficits. Over time, the mismatch between ATP demand and supply, compounded by mitochondrial dysfunction and disrupted astrocyte–neuron metabolic support, contributes to progressive neuronal dysfunction and cognitive impairment in individuals with T2DM.
The authors emphasize that the cascade from metabolic disturbance to •NO dysregulation, vascular dysfunction, and cognitive decline forms a mechanistic link tying systemic metabolic disease to brain health.
This review integrates mechanistic studies positioning nitric oxide dysregulation as a central driver of neurovascular and metabolic dysfunction in type 2 diabetes, connecting impaired cerebral perfusion, disrupted neurovascular coupling, and vascular remodelling to cognitive decline. The abstract and figures illustrate both the healthy role of •NO in NVC and the pathogenic shift occurring in T2DM. Specific therapeutic interventions, clinical trial results, or quantitative outcome measures are not presented in the abstract; details beyond the mechanistic synthesis were not reported in the source abstract. The review therefore highlights a mechanistic framework that may inform future research and therapeutic strategies but does not itself report clinical efficacy data in the abstract.